Kevin O'Reilly
Research interests: Biomechanics, Exercise Physiology, Sensory Motor studies, Cancer Research, Monoclonal Antibodies, Fermentation Technology, Electronics Construction and Repair.
Javier Menéndez, Li-qing Jin, Armando G. Poeppl, K. O'Reilly, Rachelle Brunet, Julie Grabell, Ashwani K. Gupta, John E. Dick, Daniel de Souza Pereira, David S. F. Young (2008). 506 POSTER The apogenic anti-CD9 antibody, AR40A746.2.3, inhibits tumor growth in breast and pancreatic cancer and targets cancer stem cells in acute myeloid leukemia. September 2008 EJC Supplements 6(12):161-161
Baldwin C. Mak, Fortunata McConkey, Ningping Feng, K. O'Reilly, Sui-Wah Fung, Marina Wang, Sandra Chau, Susan E. Hahn, Daniel de Matos Pereira, D S Young (2008). 517 POSTER A monoclonal antibody (AR36A36.11.1) with potent in vivo efficacy in multiple human cancer models targets CD59. September 2008 EJC Supplements 6(12):164-164
L da Cruz, K. O'Reilly, Fortunata McConkey, Xian Wang, Tetyana Antoshchenko, Natasha Aziz, Ashwani Kumar Gupta, Susan Songsuk Hahn, Daniel de Souza Pereira, D S Young (2008). 538 POSTER ARH460-16-2, targeting the CD44 cancer stem cell marker, uses multiple mechanisms to achieve its therapeutic anti-cancer effects. September 2008 EJC Supplements 6(12):170-170
S. E. Hahn, L. A. da Cruz, D. Sayegh, A. Ferry, K. O’Reilly, D. S. Pereira, D. B. Rubinstein, H. Findlay, D. S. Young (2007). Therapeutic monoclonal antibodies target phenotypically-differing human breast cancer June 2007 Journal of Clinical Oncology 25(18_suppl):13510-13510